Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Business Wire•19/10/2026•06:59 ET
0
Key Highlights
- ➤12 oral presentations and nearly 60 disclosures span BMS’s ESMO 2026 oncology program
- ➤Pumitamig Phase 2 ROSETTA Lung-107 data target metastatic non-small cell lung cancer
- ➤Iza-bren Phase 3 disclosures cover EGFR-mutated NSCLC and HR+/HER2- breast cancer
- ➤Opdivo plus Yervoy long-term survival results will be presented in a late-breaking Phase 3 session
- ➤Pumitamig is jointly developed with BioNTech; iza-bren studies are sponsored by Biokin
Expert Statements
Cristian Massacesi, MD, Executive vice president, chief medical officer and head of Development, Bristol Myers Squibb
“At ESMO 2026, we will share important data across both emerging and established modalities. From new Phase 3 results for iza-bren and new findings for pumitamig, to long-term survival data for Opdivo( ®) plus Yervoy( ®), these results reflect the breadth of our oncology pipeline, and our focus on translating differentiated science into meaningful, durable outcomes for patients.”
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Late-breaking Phase 3 disclosures for izalontamab brengitecan (iza-bren), a potential first-in-class EGFR × HER3 bispecific ADC, in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01)
Get started
Create a free account to read the full story.